Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cardiovascular Disorders
Published in: BMC Cardiovascular Disorders 1/2019

Open Access 01-12-2019 | Subarachnoid Hemorrhage | Research article

Prognostic significance of factor XIIIA promoter methylation status in aneurysmal subarachnoid haemorrhage (aSAH)

Authors: S. Arati, G. K. Chetan, M. K. Sibin, Dhananjaya I. Bhat, Vikas Vazhayil, K. V. L. Narasingarao

Published in: BMC Cardiovascular Disorders | Issue 1/2019

Login to get access

Abstract

Background

Aneurysmal subarachnoid hemorrhage is a life- threatening condition with high rate of disability and mortality. Apolipoprotein E (APOE) and Factor XIIIA (F13A) genes are involved in the pathogenetic mechanism of aneurysmal subarachnoid haemorrhage (aSAH).
We evaluated the association of promoter methylation status of APOE and F13A gene and risk of aSAH.

Methods

For evaluating the effect of hypermethylation in the promoter region of these genes with risk of aSAH, we conducted a case -control study with 50 aSAH patients and 50 healthy control. The methylation pattern was analysed using methylation specific PCR. The risk factors associated with poor outcome after aSAH was also analysed in this study. The outcome was assessed using Glasgow outcome score (GOS) after 3 months from the initial bleed.

Results

The frequency of APOE and F13A methylation pattern showed insignificant association with risk of aSAH in this study. Gender stratification analysis suggests that F13A promoter methylation status was significantly associated with the risk of aSAH in male gender. Age, aneurysm located at the anterior communicating artery and diabetes mellitus showed significant association with poor outcome after aSAH.

Conclusion

There was no significant association with APOE promoter methylation with the risk as well as outcome of patients after aSAH. F13A promoter methylation status was significantly associated with risk of aSAH in male gender, with no significant association with outcome after aSAH.
Literature
1.
2.
Wermer MJ, Van der Schaaf IC, Algra A, Rinkel GJ. Risk of rupture of unruptured intracranial aneurysms in relation to patient and aneurysm characteristics. Stroke. 2007;38(4):1404–10.PubMedCrossRef
3.
Soriano-Tárraga C, Jiménez-Conde J, Giralt-Steinhauer E, Mola M, Ois Á, Rodríguez-Campello A, Cuadrado-Godia E, Fernández-Cadenas I, Carrera C, Montaner J, Elosua R. Global DNA methylation of ischemic stroke subtypes. PLoS One. 2014;9(4):96543.CrossRef
4.
Moore LD, Le T, Fan G. DNA methylation and its basic function. Neuropsychopharmacology. 2013;38(1):23.PubMedCrossRef
5.
Juvela S, Siironen J, Lappalainen J. Apolipoprotein E genotype and outcome after aneurysmal subarachnoid hemorrhage. J Neurosurg. 2009;110(5):989–95.PubMedCrossRef
6.
Chalouhi N, Ali MS, Jabbour PM, Tjoumakaris SI, Gonzalez LF, Rosenwasser RH, Koch WJ, Dumont AS. Biology of intracranial aneurysms: role of inflammation. J Cereb Blood Flow Metab. 2012;32(9):1659–76.PubMedPubMedCentralCrossRef
7.
Grimaldi V, Vietri MT, Schiano C, Picascia A, De Pascale MR, Fiorito C, Casamassimi A, Napoli C. Epigenetic reprogramming in atherosclerosis. Curr Atheroscler Rep. 2015;17(2):476.PubMedCrossRef
8.
Paik YK, Chang DJ, Reardon CA, Davies GE, Mahley RW, Taylor JM. Nucleotide sequence and structure of the human apolipoprotein E gene. Proc Natl Acad Sci. 1985;82(10):3445–9.PubMedCrossRef
9.
Wu HT, Ruan J, Zhang XD, Xia HJ, Jiang Y, Sun XC. Association of promoter polymorphism of apolipoprotein E gene with cerebral vasospasm after spontaneous SAH. Brain Res. 2010;1362:112–6.PubMedCrossRef
10.
Bizzarro A, Seripa D, Acciarri A, Matera MG, Pilotto A, Tiziano FD, Brahe C, Masullo C. The complex interaction between APOE promoter and AD: an Italian case–control study. Eur J Hum Genet. 2009;17(7):938.PubMedPubMedCentralCrossRef
11.
Larsen F, Solheim J, Prydz H. A methylated CpG island 3'in the apolipoprotein-E gene does not repress its transcription. Hum Mol Genet. 1993;2(6):775–80.PubMedCrossRef
12.
Maloney B, Ge YW, Alley GM, Lahiri DK. Important differences between human and mouse APOE gene promoters: limitation of mouse APOE model in studying Alzheimer’s disease. J Neurochem. 2007;103(3):1237–57.PubMedCrossRef
13.
Shi DY, Wang SJ. Advances of Coagulation Factor XIII. Chinese Med J. 2017;130(2):219.
14.
Aleman MM, Byrnes JR, Wang JG, Tran R, Lam WA, Di Paola J, Mackman N, Degen JL, Flick MJ, Wolberg AS. Factor XIII activity mediates red blood cell retention in venous thrombi. J Clin Invest. 2014;124:3590.PubMedPubMedCentralCrossRef
15.
Ichinose A, Davie EW. Characterization of the gene for the a subunit of human factor XIII (plasma transglutaminase), a blood coagulation factor. Proc Natl Acad Sci. 1988;85:5829–33.PubMedCrossRef
16.
Dorgalaleh A, Alizadeh S, Tabibian S, Taregh B, Karimi M. The PAI-I Gene 4G/5G polymorphism and central nervous system bleeding in factor XIII deficiency. Blood. 2013;4782.
17.
18.
Reiner AP, Schwartz SM, Frank MB, Longstreth WT, Hindorff LA, Teramura G, Rosendaal FR, Gaur LK, Psaty BM, Siscovick DS. Polymorphisms of coagulation factor XIII subunit a and risk of nonfatal hemorrhagic stroke in young white women. Stroke. 2001;32(11):2580–7.PubMedCrossRef
19.
Yang Z, Eton D, Zheng F, Livingstone AS, Yu H. Effect of tissue plasminogen activator on vascular smooth muscle cells. J Vasc Surg. 2005;42(3):532–8.PubMedCrossRef
20.
Ladenvall C, Csajbok L, Nylén K, Jood K, Nellgård B, Jern C. Association between factor XIII single nucleotide polymorphisms and aneurysmal subarachnoid hemorrhage. J Neurosurg. 2009;110(3):475–81.PubMedCrossRef
21.
Rosengart AJ, Schultheiss KE, Tolentino J, Macdonald RL. Prognostic factors for outcome in patients with aneurysmal subarachnoid hemorrhage. Stroke. 2007;38(8):2315–21.PubMedCrossRef
22.
Lonjon M, Pennes F, Sedat J, Bataille B. Epidemiology, genetic, natural history and clinical presentation of giant cerebral aneurysms. Neurochirurgie. 2015;61(6):361–5.PubMedCrossRef
23.
Kim S, Kaang BK. Epigenetic regulation and chromatin remodeling in learning and memory. Exp Mol Med. 2017;49(1):281.CrossRef
24.
Packard RR, Libby P. Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction. Clin Chem. 2008;54(1):24–38.PubMedCrossRef
25.
26.
Huang Y, Mahley RW. Apolipoprotein E: structure and function in lipid metabolism, neurobiology, and Alzheimer's diseases. Neurobiol Dis. 2014;72:3–12.PubMedCrossRef
27.
Kordi-Tamandani DM, Najafi M, Mojahad A. Apoe and cpt1-a promoter methylation and expression profiles in patients with schizophrenia. Gene Cell Tissue. 2014;1:1.CrossRef
28.
Lambert JC, Coyle N, Lendon C. The allelic modulation of apolipoprotein E expression by oestrogen: potential relevance for Alzheimer’s disease. J Med Genet. 2004;41(2):104–12.PubMedPubMedCentralCrossRef
29.
Liu H, Mao P, Xie C, Xie W, Wang M, Jiang H. Apolipoprotein E polymorphism and the risk of intracranial aneurysms in a Chinese population. BMC Neurol. 2016;16(1):14.PubMedPubMedCentralCrossRef
30.
Tang J, Zhao J, Zhao Y, Wang S, Chen B, Zeng W. Apolipoprotein e ϵ4 and the risk of unfavorable outcome after aneurysmal subarachnoid hemorrhage. Surg Neurol. 2003;60:391–6.PubMedCrossRef
31.
Kaushal R, Woo D, Pal P, Haverbusch M, Xi H, Moomaw C, Sekar P, Kissela B, Kleindorfer D, Flaherty M, Sauerbeck L. Subarachnoid hemorrhage: tests of association with apolipoprotein E and elastin genes. BMC Med Genet. 2007;8:49.PubMedPubMedCentralCrossRef
32.
Schröder V, Kohler HP. New developments in the area of factor XIII. J Thromb Haemost. 2013;11(2):234–44.CrossRef
33.
Lu S, Davies PJ. Regulation of the expression of the tissue transglutaminase gene by DNA methylation. Proc Natl Acad Sci. 1997;94(9):4692–7.PubMedCrossRef
34.
Cacciamani T, Virgili S, Centurelli M, Bertoli E, Eremenko T, Volpe P. Specific methylation of the CpG-rich domains in the promoter of the human tissue transglutaminase gene. Gene. 2002;297:103–12.PubMedCrossRef
35.
Kida M, Souri M, Yamamoto M, Saito H, Ichinose A. Transcriptional regulation of cell type-specific expression of the TATA-less a subunit gene for human coagulation factor XIII. J Biol Chem. 1999;274(10):6138–47.PubMedCrossRef
36.
Dorgalaleh A, Rashidpanah J. Blood coagulation factor XIII and factor XIII deficiency. Blood Rev. 2016;30:461–75.PubMedCrossRef
37.
Richardson VR, Cordell P, Standeven KF, Carter AM. Substrates of factor XIII-A: roles in thrombosis and wound healing. Clin Sci. 2013;124(3):123–37.PubMedCrossRef
38.
Ruigrok YM, Slooter AJ, Rinkel GJ, Wijmenga C, Rosendaal FR. Genes influencing coagulation and the risk of aneurysmal subarachnoid hemorrhage, and subsequent complications of secondary cerebral ischemia and rebleeding. Acta Neurochir. 2010;152(2):257–62.PubMedCrossRef
39.
Ariens RA, Lai TS, Weisel JW, Greenberg CS, Grant PJ. Role of factor XIII in fibrin clot formation and effects of genetic polymorphisms. Blood. 2002;100:743–54.PubMedCrossRef
40.
Qureshi SA, Bashir MU, Yaqinuddin A. Utility of DNA methylation markers for diagnosing cancer. Int J Surg. 2010;8(3):194–8.PubMedCrossRef
41.
42.
Woodson K, Mason J, Choi SW, Hartman T, Tangrea J, Virtamo J, Taylor PR, Albanes D. Hypomethylation of p53 in peripheral blood DNA is associated with the development of lung cancer. Cancer Epidemiol Prev Biomarkers. 2001;10(1):69–74.
43.
Li L, Choi JY, Lee KM, Sung H, Park SK, Oze I, Pan KF, You WC, Chen YX, Fang JY, Matsuo K. DNA methylation in peripheral blood: a potential biomarker for cancer molecular epidemiology. J Epidemiol. 2012;22(5):384–94.PubMedPubMedCentralCrossRef
44.
Ma Y, Smith CE, Lai CQ, Irvin MR, Parnell LD, Lee YC, Pham L, Aslibekyan S, Claas SA, Tsai MY, Borecki IB. Genetic variants modify the effect of age on APOE methylation in the G enetics of L ipid L owering D rugs and D iet N etwork study. Aging Cell. 2015;14(1):49–59.PubMedCrossRef
Metadata
Title
Prognostic significance of factor XIIIA promoter methylation status in aneurysmal subarachnoid haemorrhage (aSAH)
Authors
S. Arati
G. K. Chetan
M. K. Sibin
Dhananjaya I. Bhat
Vikas Vazhayil
K. V. L. Narasingarao
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Cardiovascular Disorders / Issue 1/2019
Electronic ISSN: 1471-2261
DOI
https://doi.org/10.1186/s12872-019-1146-8

Other articles of this Issue 1/2019

BMC Cardiovascular Disorders 1/2019 Go to the issue

Research article

Dynamic predictive accuracy of electrocardiographic biomarkers of sudden cardiac death within a survival framework: the Atherosclerosis Risk in Communities (ARIC) study

Case report

Epicardial cardiac cavernous Haemangioma-a case report

Case report

Case report - coronary vasospasm in transplanted heart: a puzzling phenomenon

Research article

Review of the cardiovascular safety of dipeptidyl peptidase-4 inhibitors and the clinical relevance of the CAROLINA trial

Study protocol

Harnessing technology and molecular analysis to understand the development of cardiovascular diseases in Asia: a prospective cohort study (SingHEART)

Research article

Increased urinary adiponectin level is associated with contrast-induced nephropathy in patients undergoing elective percutaneous coronary intervention